demonstrated that inhibition of fibroblast growth factor receptor 4 (FGFR4) can trigger ferroptosis in breast cancer cells through the β-catenin/TCF4-SLC7A11/FPN1 axis, presenting a novel target for overcoming resistance in HER2-positive breast cancer (23). Here, ERBB2 is linked to breast carcinoma.